New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
07:23 EDTDNDN, SNSSSunesis appoints Joseph DePinto as Chief Commercial Officer
Sunesis Pharmaceuticals (SNSS) announced the appointment of Joseph DePinto to the newly created position of executive vice president and Chief Commercial Officer. Prior to joining Sunesis, DePinto was Executive Vice President, Global Commercial Operations at Dendreon (DNDN).
News For SNSS;DNDN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:07 EDTSNSSSunesis publishes REVEAL-1 trial results
Subscribe for More Information
November 19, 2014
07:05 EDTSNSSSunesis publishes vosaroxin Phase 1b/2 AML trial results
Subscribe for More Information
November 18, 2014
07:37 EDTSNSSStifel to hold a conference
Subscribe for More Information
November 17, 2014
11:56 EDTSNSSSunesis jumps after announcing plans to present data from VALOR trial
Subscribe for More Information
November 14, 2014
16:24 EDTSNSSBiotechnology Value Fund reports 5.1% passive stake in Sunesis
November 12, 2014
10:00 EDTDNDNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:30 EDTDNDNDendreon upgraded to Neutral from Sell at Roth Capital
Subscribe for More Information
November 10, 2014
10:14 EDTDNDNHigh option volume stocks
High option volume stocks: UN PAGP PHH RGLS DF URA CERS DNDN LGF CALL
09:35 EDTDNDNActive equity options trading
Subscribe for More Information
09:20 EDTDNDN, SNSSOn The Fly: Pre-market Movers
Subscribe for More Information
07:13 EDTSNSSSunesis reports Q3 EPS (25c), consensus (17c)
Subscribe for More Information
05:52 EDTDNDNDendreon files for Chapter 11 bankruptcy
Dendreon announced that it has reached agreements on the terms of a financial restructuring with certain holders of the company’s 2.875% Convertible Senior Notes due 2016 representing approximately 84% of the $620M aggregate principal amount of the 2016 Notes. Under the terms of the agreements, the financial restructuring may take the form of a stand-alone recapitalization or a sale of the company or its assets. The transactions under the agreements will enable continued delivery of Provenge without disruption or impact to access for providers and appropriate patients in need of this revolutionary personalized immunotherapy treatment, Dendreon said. To implement the financial restructuring, Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware on November 10. Dendreon said it has "significant liquidity to support all of its operations during the restructuring process," with approximately $100M of cash, cash equivalents and investments on hand as of November 7, and does "not anticipate the need to raise any incremental financing in connection with the restructuring process." The stock closed Friday up 11c to 94c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use